On July 3, 2025, HC Wainwright & Co. reiterated its coverage on Zymeworks (ZYME, Financial), maintaining a "Neutral" rating. The analyst behind the rating, Robert Burns, provided a consistent assessment of the stock, aligning with prior evaluations.
Zymeworks (ZYME, Financial) continues to hold a target price of $13.00 USD, unchanged from previous forecasts. This consistent price target suggests stability in the company's expected performance as observed by HC Wainwright & Co.
The decision to maintain the current rating and price target reflects the analyst's view of Zymeworks (ZYME, Financial) within the broader market context. Investors following Zymeworks may consider this insight as part of their portfolio strategy. HC Wainwright & Co.'s analysis provides a steady perspective on the expected trajectory of the stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Zymeworks Inc (ZYME, Financial) is $22.39 with a high estimate of $30.00 and a low estimate of $13.00. The average target implies an upside of 73.83% from the current price of $12.88. More detailed estimate data can be found on the Zymeworks Inc (ZYME) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Zymeworks Inc's (ZYME, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Zymeworks Inc (ZYME, Financial) in one year is $19.25, suggesting a upside of 49.46% from the current price of $12.88. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Zymeworks Inc (ZYME) Summary page.
